Therapeutic Asset Ratings

329 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
io102-io103 Melanoma	IO Biotech	P3	B (56)
Lifileucel Melanoma	Iovance Biotherapeutics, Inc.	P3	B (56)
LISPRO-PH20 COMPONENT RHUPH20 Melanoma	Bristol-Myers Squibb	P3	B (56)
L-Phenylalanine, L-?-aspartyl-L-threonyl-L-leucyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-leucyl-L-?-glutamyl-L-isoleucyl-L-alanyl-L-seryl-L-cysteinyl-L-leucyl-L-?-glutamyl-L-lysyl-L-alanyl-L-leucyl-L-glutaminyl-L-valyl- Melanoma	IO Biotech	P3	B (56)
oh2 Melanoma	Binhui Biopharmaceutical Co., Ltd.	P3	B (56)
Enzalutamide Melanoma	MacroGenics	P2	B (56)
Letrozole Melanoma	Novartis Pharmaceuticals	P2	B (56)
Metformin Melanoma	Dan Zandberg	P2	B (56)
Pucotenlimab Melanoma	Binhui Biopharmaceutical Co., Ltd.	P2	B (56)
Pyrotinib Melanoma	HiFiBiO Therapeutics	P2	B (56)
rc48-adc Melanoma	HiFiBiO Therapeutics	P2	B (56)
Tislelizumab Melanoma	HiFiBiO Therapeutics	P2	B (56)
Dfn-15 Melanoma	Roswell Park Cancer Institute	P2	CCC (55)
FULVESTRANT Melanoma	Rain Oncology Inc	P2	CCC (55)
gc101 Melanoma	Shanghai Juncell Therapeutics	P2	CCC (55)
her2bbζ/cd19t+ t cells Melanoma	M.D. Anderson Cancer Center	P2	CCC (55)
Hydroxychloroquine Melanoma	N.N. Petrov National Medical Research Center of Oncology	P2	CCC (55)
LEUPROLIDE Melanoma	Novartis Pharmaceuticals	P2	CCC (55)
Recombinant Flt3 Ligand Melanoma	University of Southern California	P2	CCC (55)
Regorafenib Melanoma	Neonc Technologies, Inc.	P2	CCC (55)
Veliparib Melanoma	National Cancer Institute (NCI)	P2	CCC (55)
Abp 206 Melanoma	Amgen	P3	CCC (54)
Infliximab Melanoma	Massachusetts General Hospital	P2	CCC (54)
Entrectinib Melanoma	Cancer Research UK	P2/3	CCC (54)
Sonazoid Melanoma	The Netherlands Cancer Institute	P2/3	CCC (54)

Showing 51 to 75 of 329 assets

PreviousPage 3 of 14Next